Indivior
 | |
| Company type | Public company |
|---|---|
| LSE: INDV | |
| Industry | pharmaceuticals |
| Founded | 1994 |
| Headquarters | Richmond, Virginia |
Key people | Howard Pien, Chairman Shaun Thaxter, CEO |
| Products | Subutex/Subuxone |
| Revenue | $1,005 million (2018)[1] |
| $292 million (2018)[1] | |
| $275 million (2018)[1] | |
Number of employees | 915 (2018)[1] |
| Website | www.indivior.com/ |
Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange.
History
The company was established as the Buprenorphine division of Reckitt Benckiser in 1994.[2] In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.[3] By February 2015 the company was capitalised at £2.3 billion on the London Stock Exchange.[4]
In 2019, Indivior was indicted over claims that it had made false marketing claims about the effectiveness of its drug, Suboxone, and had concocted a scheme to direct patients towards doctors who were likely to prescribe Suboxone. Reckitt Benckiser has settled with the Justice Department to pay $1.4 billion to resolve a U.S. Federal investigation into sales and marketing of opioid addiction treatment.[5][6][7]
Operations
The company's main products are Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction.[2] Other products include remedies for cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.[8]
-
Suboxone sublingual film
References
- ^ a b c d "Annual Report 2018" (PDF). Indivior. Retrieved 18 March 2019.
- ^ a b "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
- ^ "RB complete demerger of Indivior - RB". RB. 23 December 2014. Archived from the original on 29 March 2015. Retrieved 21 March 2015.
- ^ "Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?". Retrieved 22 March 2015.
- ^ Reuters (11 July 2019). "Reckitt to Pay $1.4 Billion to End Long-Running Indivior Probes". The New York Times. ISSN 0362-4331. Retrieved 11 July 2019.
{{cite news}}:|last=has generic name (help) - ^ admin. "Reckitt to pay $1.4 billion to end long-running Indivior probes". Retrieved 11 July 2019.
- ^ "Reckitt to pay $1.4 billion to end long-running Indivior probes". Reuters. 11 July 2019. Retrieved 11 July 2019.
- ^ "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.